172 related articles for article (PubMed ID: 23930470)
1. A comprehensive response to the opioid epidemic: Hazelden's approach.
Seppala MD
Minn Med; 2013 Mar; 96(3):45-7. PubMed ID: 23930470
[TBL] [Abstract][Full Text] [Related]
2. Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population.
McDermott KA; Griffin ML; Connery HS; Hilario EY; Fiellin DA; Fitzmaurice GM; Weiss RD
J Clin Psychiatry; 2015 Feb; 76(2):189-94. PubMed ID: 25562462
[TBL] [Abstract][Full Text] [Related]
3. The rampant abuse of prescription pain medications.
Falkowski C
Minn Med; 2013 Mar; 96(3):38-41. PubMed ID: 23930468
[TBL] [Abstract][Full Text] [Related]
4. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
Curcio F; Franco T; Topa M; Baldassarre C;
Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
[TBL] [Abstract][Full Text] [Related]
5. Access to treatment for opioid dependence in rural America: challenges and future directions.
Sigmon SC
JAMA Psychiatry; 2014 Apr; 71(4):359-60. PubMed ID: 24500040
[No Abstract] [Full Text] [Related]
6. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence.
Ridge G; Gossop M; Lintzeris N; Witton J; Strang J
J Subst Abuse Treat; 2009 Jul; 37(1):95-100. PubMed ID: 19004598
[TBL] [Abstract][Full Text] [Related]
7. The Opioid Crisis and the Physician's Role in Contributing to its Resolution: Step One--Prevention of Overdoses.
Wolfe S; Bouffard DL; Modesto-Lowe V
Conn Med; 2016; 80(6):325-34. PubMed ID: 27509638
[TBL] [Abstract][Full Text] [Related]
8. The Opioid Epidemic: What Does it Mean for Nurses?
Leahy LG
J Psychosoc Nurs Ment Health Serv; 2017 Jan; 55(1):18-23. PubMed ID: 28135387
[TBL] [Abstract][Full Text] [Related]
9. The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.
Horyniak D; Dietze P; Larance B; Winstock A; Degenhardt L
Int J Drug Policy; 2011 Mar; 22(2):167-71. PubMed ID: 21112758
[TBL] [Abstract][Full Text] [Related]
10. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction.
Kolodny A; Courtwright DT; Hwang CS; Kreiner P; Eadie JL; Clark TW; Alexander GC
Annu Rev Public Health; 2015 Mar; 36():559-74. PubMed ID: 25581144
[TBL] [Abstract][Full Text] [Related]
11. Neonatal drug withdrawal.
Barthell JE; Mrozek JD
Minn Med; 2013 Mar; 96(3):48-50. PubMed ID: 23930471
[TBL] [Abstract][Full Text] [Related]
12. Statement of the American Society Of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction.
Kraus ML; Alford DP; Kotz MM; Levounis P; Mandell TW; Meyer M; Salsitz EA; Wetterau N; Wyatt SA;
J Addict Med; 2011 Dec; 5(4):254-63. PubMed ID: 22042215
[TBL] [Abstract][Full Text] [Related]
13. Office-based buprenorphine treatment for opioid-dependent patients.
McCance-Katz EF
Harv Rev Psychiatry; 2004; 12(6):321-38. PubMed ID: 15764468
[TBL] [Abstract][Full Text] [Related]
14. Opioid drugs in maintenance and detoxification treatment of opiate addiction; addition of buprenorphine and buprenorphine combination to list of approved opioid treatment medications. Interim final rule.
Substance Abuse and Mental Health Services Administration (SAMHSA), Department of Health and Human Services
Fed Regist; 2003 May; 68(99):27937-9. PubMed ID: 12762334
[TBL] [Abstract][Full Text] [Related]
15. Finding a feasible solution. States employ different legislative strategies to curb misuse.
Milhofer J
Minn Med; 2013 Mar; 96(3):52-4. PubMed ID: 23930472
[No Abstract] [Full Text] [Related]
16. Misuse of buprenorphine maintenance treatment since introduction of its generic forms: OPPIDUM survey.
Nordmann S; Frauger E; Pauly V; Orléans V; Pradel V; Mallaret M; Thirion X; Micallef J
Pharmacoepidemiol Drug Saf; 2012 Feb; 21(2):184-90. PubMed ID: 22109894
[TBL] [Abstract][Full Text] [Related]
17. The Opioid Epidemic and the Minnesota Board of Medical Practice.
Waisbren SJ
Minn Med; 2016; 99(3):39-41. PubMed ID: 27323522
[TBL] [Abstract][Full Text] [Related]
18. Use and misuse of opioid replacement therapies: a Queensland study.
Smirnov A; Kemp R
Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
[TBL] [Abstract][Full Text] [Related]
19. [Should high-dose buprenorphine be withdrawn from the French market?].
Rolland B; Muyssen A; Danel T; Cottencin O
Rev Epidemiol Sante Publique; 2013 Apr; 61(2):91-2. PubMed ID: 23489947
[No Abstract] [Full Text] [Related]
20. Opioid drugs in maintenance and detoxification treatment of opiate addiction; proposed modification of dispensing restrictions for buprenorphine and buprenorphine combination as used in approved opioid treatment medications. Final rule.
Substance Abuse and Mental Health Services Administration (SAMHSA), Department of Health and Human Services (HHS)
Fed Regist; 2012 Dec; 77(235):72752-61. PubMed ID: 23227572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
